SPRO logo

Spero Therapeutics (SPRO) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 November 2017

Indexes:

Not included

Description:

Spero Therapeutics is a biopharmaceutical company focused on developing innovative treatments for bacterial infections. They aim to address antibiotic resistance by creating new therapies that target difficult-to-treat infections, improving patient outcomes and public health. Their research emphasizes advanced drug development and collaboration with healthcare professionals.

Key Details

Price

$1.03

Annual Revenue

$96.73 M(+99.13% YoY)

Annual EPS

$0.43(+134.96% YoY)

PE Ratio

12.88(-90.60% YoY)

Beta

0.59

Events Calendar

Earnings

Next earnings date:

Mar 13, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 13, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

20 Dec '24 Evercore ISI Group
In-Line
02 Dec '24 HC Wainwright & Co.
Buy
18 Nov '24 TD Cowen
Hold
15 Nov '24 Cantor Fitzgerald
Overweight
04 Nov '24 HC Wainwright & Co.
Buy
03 Oct '24 HC Wainwright & Co.
Buy
06 Aug '24 TD Cowen
Buy
06 Aug '24 HC Wainwright & Co.
Buy
06 Aug '24 Cantor Fitzgerald
Overweight
16 May '24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SPRO
zacks.com16 December 2024

Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
SPRO
zacks.com14 November 2024

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago.

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
SPRO
seekingalpha.com09 August 2024

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET Company Participants Shai Biran - Senior Director Investor Relations Sath Shukla - Chief Executive Officer Esther Rajavelu - CFO and Chief Business Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Gavin Clark-Gartner - Evercore ISI Ritu Baral - TD Cowen Operator Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
SPRO
zacks.com05 August 2024

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.23 per share a year ago.

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
SPRO
globenewswire.com29 July 2024

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline.

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
SPRO
globenewswire.com16 May 2024

Spero Therapeutics, Inc. (Nasdaq: SPRO) will be represented by its President and CEO, Sath Shukla, at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York on May 20, 2024. Shukla will participate in a fireside chat and be available for one-on-one meetings.

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
SPRO
Zacks Investment Research13 March 2024

Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to earnings of $0.55 per share a year ago.

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
SPRO
GlobeNewsWire06 March 2024

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
SPRO
GlobeNewsWire26 February 2024

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA. Details are as follows:

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript
SPRO
Seeking Alpha13 November 2023

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief Medical Officer Steve Dipalma - Interim Chief Financial Officer and Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright Good afternoon and welcome to the Spero Therapeutics Third Quarter 2023 Financial Results Conference Call.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the primary business of Spero Therapeutics?
  • What is the ticker symbol for Spero Therapeutics?
  • Does Spero Therapeutics pay dividends?
  • What sector is Spero Therapeutics in?
  • What industry is Spero Therapeutics in?
  • What country is Spero Therapeutics based in?
  • When did Spero Therapeutics go public?
  • Is Spero Therapeutics in the S&P 500?
  • Is Spero Therapeutics in the NASDAQ 100?
  • Is Spero Therapeutics in the Dow Jones?
  • When was Spero Therapeutics's last earnings report?
  • When does Spero Therapeutics report earnings?
  • Should I buy Spero Therapeutics stock now?

What is the primary business of Spero Therapeutics?

Spero Therapeutics is a biopharmaceutical company focused on developing innovative treatments for bacterial infections. They aim to address antibiotic resistance by creating new therapies that target difficult-to-treat infections, improving patient outcomes and public health. Their research emphasizes advanced drug development and collaboration with healthcare professionals.

What is the ticker symbol for Spero Therapeutics?

The ticker symbol for Spero Therapeutics is NASDAQ:SPRO

Does Spero Therapeutics pay dividends?

No, Spero Therapeutics does not pay dividends

What sector is Spero Therapeutics in?

Spero Therapeutics is in the Healthcare sector

What industry is Spero Therapeutics in?

Spero Therapeutics is in the Biotechnology industry

What country is Spero Therapeutics based in?

Spero Therapeutics is headquartered in United States

When did Spero Therapeutics go public?

Spero Therapeutics's initial public offering (IPO) was on 02 November 2017

Is Spero Therapeutics in the S&P 500?

No, Spero Therapeutics is not included in the S&P 500 index

Is Spero Therapeutics in the NASDAQ 100?

No, Spero Therapeutics is not included in the NASDAQ 100 index

Is Spero Therapeutics in the Dow Jones?

No, Spero Therapeutics is not included in the Dow Jones index

When was Spero Therapeutics's last earnings report?

Spero Therapeutics's most recent earnings report was on 14 November 2024

When does Spero Therapeutics report earnings?

The next expected earnings date for Spero Therapeutics is 13 March 2025

Should I buy Spero Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions